VANDA PHARMA (VM4.SG)
VANDA PHARMA (VM4.SG) operates in Diversified Metals & Mining.
VANDA PHARMA (VM4.SG) (VM4) - Total Liabilities
Latest total liabilities as of September 2024: €103.89 Million EUR
Based on the latest financial reports, VANDA PHARMA (VM4.SG) (VM4) has total liabilities worth €103.89 Million EUR as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
VANDA PHARMA (VM4.SG) - Total Liabilities Trend (2016–2023)
This chart illustrates how VANDA PHARMA (VM4.SG)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
VANDA PHARMA (VM4.SG) Competitors by Total Liabilities
The table below lists competitors of VANDA PHARMA (VM4.SG) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Citrine Global Corp
PINK:CTGL
|
USA | $5.22 Million |
|
CITIZEN HOLDINGS (CTZ.SG)
STU:CTZ
|
Germany | €159.31 Billion |
|
Boostheat
PA:ALBOO
|
France | €3.20 Million |
|
THE WESTERN UNION - Dusseldorf Stock Exchang
DU:W3U
|
Germany | €7.02 Billion |
|
Angel Gold Corp
PINK:ANGCF
|
USA | $59.94K |
|
WEIBO SP ADS-A
MU:2WBA
|
Germany | €3.69 Billion |
Liability Composition Analysis (2016–2023)
This chart breaks down VANDA PHARMA (VM4.SG)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VANDA PHARMA (VM4.SG)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VANDA PHARMA (VM4.SG) (2016–2023)
The table below shows the annual total liabilities of VANDA PHARMA (VM4.SG) from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €103.53 Million | -3.29% |
| 2022-12-31 | €107.05 Million | +20.46% |
| 2021-12-31 | €88.86 Million | +10.82% |
| 2020-12-31 | €80.19 Million | +10.15% |
| 2019-12-31 | €72.80 Million | +28.38% |
| 2018-12-31 | €56.71 Million | -23.41% |
| 2017-12-31 | €74.04 Million | -6.33% |
| 2016-12-31 | €79.04 Million | -- |